Administration of recombinant thrombomodulin before progression of disease causing disseminated intravascular coagulation might be better compared with administration after progression of disease

详细信息    查看全文

• 作者：Tomoaki Yatabe ; Ryu Nakamura ; Naoko Kumagai ; Tatsuo Iiyama…
• 关键词：Recombinant thrombomodulin ; Disseminated intravascular coagulation ; Retrospective analysis
• 刊名：Journal of Intensive Care
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：2
• 期：1
• 全文大小：309KB
• 参考文献：1.Singh B, Hanson AC, Alhurani R, Wang S, Herasevich V, Cartin-Ceba R, Kor DJ, Gangat N, Li G: Trends in the incidence and outcomes of disseminated intravascular coagulation in critically ill patients (2004鈥?010): a population-based study. CHEST 2013, 143:1235鈥?242.PubMed CrossRef
  2.Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M, Aoki N: Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007, 5:31鈥?1.PubMed CrossRef
  3.Vincent JL, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, Hoste E, Levy H, Hirman J, Levi M, Daga M, Kutsogiannis DJ, Crowther M, Bernard GR, Devriendt J, Puigserver JV, Blanzaco DU, Esmon CT, Parrillo JE, Guzzi L, Henderson SJ, Pothirat C, Mehta P, Fareed J, Talwar D, Tsuruta K, Gorelick KJ, Osawa Y, Kaul I: A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 2013, 41:2069鈥?079.PubMed CrossRef
  4.Kato T, Sakai T, Kato M, Hagihara M, Hasegawa T, Matsuura K, Nakagawa T: Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study. Thromb J 2013, 11:3.PubMed Central PubMed CrossRef
  5.Gando S, Saitoh D, Ogura H, Fujishima S, Mayumi T, Araki T, Ikeda H, Kotani J, Kushimoto S, Miki Y, Shiraishi SI, Suzuki K, Suzuki Y, Takeyama N, Takuma K, Tsuruta R, Yamaguchi Y, Yamashita N, Aikawa N: A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis. Crit Care 2013, 17:R111.PubMed Central PubMed CrossRef
  6.Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Intensive Care Med 2013, 39:165鈥?28.PubMed CrossRef
  7.Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008, 34:17鈥?0.PubMed Central PubMed CrossRef
  8.Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699鈥?09.PubMed CrossRef
  9.Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Fran莽ois B, Guy JS, Br眉ckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353:1332鈥?341.PubMed CrossRef
  10.Ito T, Maruyama I: Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost 2011, 9(Suppl 1):168鈥?73.PubMed CrossRef
  11.Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, G氓rdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD: Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012, 366:2055鈥?064.PubMed CrossRef
  
• 作者单位：Tomoaki Yatabe (1)
  Ryu Nakamura (1)
  Naoko Kumagai (2)
  Tatsuo Iiyama (2)
  Koichi Yamashita (1)
  Masataka Yokoyama (1)
  
  1. Department of Anesthesiology and Intensive Care Medicine, Kochi Medical School, Kohasu, Oko-cho, Nankoku City, Kochi, 783-8505, Japan
  2. Department of Advanced Medical Technologies, Kochi Medical School, Kohasu, Oko-cho, Nankoku city, Kochi, 783-8505, Japan
  
• 刊物类别：Intensive / Critical Care Medicine;
• 刊物主题：Intensive / Critical Care Medicine;
• 出版者：BioMed Central
• ISSN：2052-0492

文摘

Background As disseminated intravascular coagulation (DIC) causes multiple organ failure, recombinant thrombomodulin (rTM) is widely used in Japan for treating DIC. However, the optimal timing of rTM administration has not yet been determined. We hypothesized that the administration of rTM before progression of disease causing DIC might be better for the treatment of DIC than that after progression of disease.